Coronavirus Update: Moderna Set For Bigger Test As Vaccine Trials Begin In Older People
Plus: Inhaled Remdesivir Trials, Clover Gets More Funding
Executive Summary
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.
You may also be interested in...
Coronavirus Update: Regeneron Gets Warp Speed Funding, Conflict Slowing Moderna's Progress
Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.
Amid Supply Concerns, EU Approves Gilead’s Remdesivir
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.
Coronavirus Update: Clover Begins Twin Track Trials With GSK And Dynavax
Clover enters the clinical trial stage in race to develop a vaccine, while the UK moves to protect a range of key industries from foreign takeover, including vaccines manufacturers. Meanwhile, confirmed cases in Beijing continue to rise.